Get the Stockscreener App
66.82
1.87%
-1.27
Pre-market:
66.29
-0.53
-0.79%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $66.82, with a volume of 4.57M.
It is down -1.87% in the last 24 hours and up +1.41% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$68.09
Open:
$67.24
24h Volume:
4.57M
Relative Volume:
0.41
Market Cap:
$136.49B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
18.76
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+0.36%
1M Performance:
+1.41%
6M Performance:
+7.20%
1Y Performance:
+43.11%
1-Day Range:
$66.58
$67.72
1-Week Range:
$65.91
$68.24
52-Week Range:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
66.82 | 133.74B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Company $BMY Shares Acquired by Amundi - MarketBeat
Bristol Myers Squibb stock heads into the open after a 1.9% slide - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $99.23 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
TD Waterhouse Canada Inc. Buys 53,881 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Why Davy thinks Bristol-Myers Squibb’s latest rally is one to cash in on - Business Post
Saudi Central Bank Purchases 67,780 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Mid American Wealth Advisory Group Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup - ChartMill
Munich Reinsurance Co Stock Corp in Munich Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by NEOS Investment Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Position Boosted by Concurrent Investment Advisors LLC - MarketBeat
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - marketwatch.com
Will Long‑Term Camzyos Data and Real‑World Evidence Change Bristol Myers Squibb's (BMY) Narrative? - simplywall.st
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - tradingview.com
Bristol-Myers Squibb stock steadies as CAR-T trial pause meets strong Q2 2026 figures - AD HOC NEWS
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths - Benzinga
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Bought by Burford Brothers Inc. - MarketBeat
Bristol Myers Squibb stock gains on Q2 beat and raised 2026 guidance - AD HOC NEWS
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - Barchart.com
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barron's
Bristol Myers Squibb stock gains on CAR-T pause and Camzyos momentum - AD HOC NEWS
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains - marketwatch.com
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - biopharmadive.com
Cellares downsizes New Jersey operations after losing BMS cell therapy contract - Fierce Pharma
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails - BioSpace
Bristol-Myers Squibb stock holds the mid-$60 range - AD HOC NEWS
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns - biopharmadive.com
Quantitative Investment Management LLC Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Wellington Management Group LLP Has $225.53 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Benjamin Edwards Inc. Acquires 18,656 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Davidson Investment Advisors Sells 15,902 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Investment Management Co. Purchases 26,360 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Unveils Five Year Camzyos Data At ESC Congress - simplywall.st
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors - The Motley Fool
Bristol Myers Squibb reports 97.4% of patients below heart blockage threshold - Stock Titan
Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value - Yahoo Finance
Archer Investment Corp Takes $1.40 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) After ZENBEXUS Approval Faces A Fully Valued Debate - simplywall.st
Glenview Trust Co Invests $5.89 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Jupiter Topco LLC Makes New Investment in Bristol Myers Squibb Company $BMY - MarketBeat
Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb - Yahoo Finance
Pure Financial Advisors LLC Invests $1.29 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Cellares suffers financial blow as Bristol Myers Squibb ends collaboration - BioProcess International
33,855 Shares in Bristol Myers Squibb Company $BMY Bought by Pingora Partners LLC - MarketBeat
Bristol-Myers Squibb (BMY) SVP and Controller Phil Holzer Sells 500 Shares - GuruFocus
Primecap Management Co. CA Takes $1.44 Billion Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):